BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 216,070 shares, a decrease of 13.4% from the December 31st total of 249,388 shares. Based on an average daily volume of 71,577 shares, the short-interest ratio is presently 3.0 days. Currently, 2.5% of the company’s stock are sold short. Currently, 2.5% of the company’s stock are sold short. Based on an average daily volume of 71,577 shares, the short-interest ratio is presently 3.0 days.

Institutional Trading of BioCardia

An institutional investor recently bought a new position in BioCardia stock. Cetera Investment Advisers purchased a new position in shares of BioCardia, Inc. (NASDAQ:BCDA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned about 0.37% of BioCardia as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 20.57% of the company’s stock.

BioCardia Stock Up 1.2%

BCDA stock traded up $0.02 during mid-day trading on Tuesday, reaching $1.23. 1,775 shares of the company traded hands, compared to its average volume of 61,831. The firm’s 50 day moving average price is $1.34 and its 200 day moving average price is $1.55. The stock has a market cap of $13.00 million, a price-to-earnings ratio of -0.83 and a beta of 0.56. BioCardia has a fifty-two week low of $1.00 and a fifty-two week high of $3.20.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Wednesday, November 12th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. On average, analysts anticipate that BioCardia will post -3.52 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on BCDA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. Wall Street Zen upgraded BioCardia to a “sell” rating in a report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.